Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors.

@article{Weir2015PatiromerIP,
  title={Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors.},
  author={Matthew R. Weir and George L. Bakris and David A. Bushinsky and Martha R. Mayo and Dahlia Garza and Yuri Stasiv and Janet Turk Wittes and Heidi Christ-schmidt and Lance Berman and Bertram Pitt},
  journal={The New England journal of medicine},
  year={2015},
  volume={372 3},
  pages={
          211-21
        }
}
BACKGROUND Hyperkalemia increases the risk of death and limits the use of inhibitors of the renin-angiotensin-aldosterone system (RAAS) in high-risk patients. We assessed the safety and efficacy of patiromer, a nonabsorbed potassium binder, in a multicenter, prospective trial. METHODS Patients with chronic kidney disease who were receiving RAAS inhibitors and who had serum potassium levels of 5.1 to less than 6.5 mmol per liter received patiromer (at an initial dose of 4.2 g or 8.4 g twice a… 

Figures and Tables from this paper

Effectiveness of patiromer in the treatment of hyperkalemia in chronic kidney disease patients with hypertension on diuretics

The serum K+-lowering efficacy and safety profile of patiromer in hyperkalemia patients with CKD was not compromised by diuretic therapy.

Patiromer induces rapid and sustained potassium lowering in patients with chronic kidney disease and hyperkalemia

Patiromer induced an early and sustained reduction in serum potassium and was well tolerated in patients with CKD and sustained hyperkalemia on RAASi, and the most common gastrointestinal adverse event was mild constipation in two patients.

Safety and Efficacy of Patiromer in Hyperkalemic Patients with CKD: A Pooled Analysis of Three Randomized Trials

Patiromer was effective for treatment of hyperkalemia and well tolerated in patients across stages of CKD, most of whom were receiving guideline-recommended RAASi therapy.

Effect of Patiromer in Hyperkalemic Patients Taking and Not Taking RAAS Inhibitors

Patiromer was effective and generally well-tolerated for hyperkalemia treatment, whether or not patients were taking RAAS inhibitors.

Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial.

Patiromer was titrated to achieve and maintain serum potassium level 5.0 mEq/L or lower, which was the most common treatment-related adverse event, mild to moderate constipation, and hypokalemia (<3.3%) over the 52 weeks.

The Role of Patiromer in Delaying the Onset of Renal Replacement Therapy in Patients with Advanced Renal Failure

A case series of four patients with Stage 4 or 5 CKD in whom the initiation of dialysis was delayed with the use of patiromer, a sodium-free, potassium-binding polymer used for the treatment of hyperkalemia is presented.

New therapies for hyperkalemia

These new therapies show promising results for the chronic management of hyperkalemia, whilst also potentially allowing for the concomitant use of RAAS inhibitors at optimal doses.

Managing hyperkalemia in high-risk patients in long-term care.

Patiromer was approved for the treatment of hyperkalemia in 2015 and has been shown to maintain normokalemia for up to 52 weeks in patients with CKD and/or HF on RAAS inhibitors, indicating a paradigm shift away from the discontinuation of guideline recommended therapies.
...

References

SHOWING 1-10 OF 32 REFERENCES

The frequency of hyperkalemia and its significance in chronic kidney disease.

The risk of hyperkalemia is increased with CKD, and its occurrence increases the odds of mortality within 1 day of the event, underscore the importance of this metabolic disturbance as a threat to patient safety in CKD.

Prediction and management of hyperkalemia across the spectrum of chronic kidney disease.

Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry?

Mild hyperkalemia is common in medical outpatients using ACE inhibitors, especially in those with renal insufficiency or congestive heart failure, however, subsequent severe hyperkAlemia is uncommon in patients younger than 70 years with normal renal function.

Combined angiotensin inhibition for the treatment of diabetic nephropathy.

Combination therapy with an ACE inhibitor and an ARB was associated with an increased risk of adverse events among patients with diabetic nephropathy and safety outcomes included mortality, hyperkalemia, and acute kidney injury.

Management of Hyperkalemia in Hospitalized Patients

Almost all the patients were treated for hyperkalemia, and Oral SPS monotherapy was the predominant treatment with the best response at the highest dose, and greater reductions in potassium were observed using a combination of treatments.

PEARL-HF: prevention of hyperkalemia in patients with heart failure using a novel polymeric potassium binder, RLY5016.

Interventions to reliably control serum K(+) during renin-angiotensin-aldosterone inhibition have not been available to date and would be of particular value with the use of mineralocorticoid receptor antagonists that have been shown to reduce mortality in patients with heart failure and a reduced left ventricular ejection fraction.

Potassium Binders in Hemodialysis Patients: A Friend or Foe?

The findings raise concern regarding cost-efficacy of this medication and lend credence to investing in traditional measures in hyperkalemia management, namely dietary compliance and adequate dialysis.

Use of aldosterone antagonists in heart failure.

Applying serum creatinine and potassium appropriateness criteria, inappropriate and potentially inappropriate use of aldosterone antagonist therapy was low and did not change over the 3-year study period.

Major Barriers against Renin–Angiotensin–Aldosterone System Blocker Use in Chronic Kidney Disease Stages 3–5 in Clinical Practice: A Safety Concern?

It was showed that hyperkalemia is the major barrier against the use of RAAS blockers in patients with CKD, and there was, however, a subset of patients who did not receive RAas blockers even without clear contraindications.